Novavax (NVAX) received a Hold rating and a $105.00 price target from Ladenburg Thalmann & Co. analyst Michael Higgins today. The company’s shares closed last Tuesday at $104.56, close to its 52-week high of $111.77.
According to TipRanks.com, Higgins ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.1% and a 30.8% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Armata Pharmaceuticals.
Novavax has an analyst consensus of Moderate Buy, with a price target consensus of $101.20.
See today’s analyst top recommended stocks >>
Based on Novavax’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $3.38 million and GAAP net loss of $25.86 million. In comparison, last year the company earned revenue of $3.98 million and had a GAAP net loss of $43.22 million.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NVAX in relation to earlier this year. Last month, Gregory Glenn, the President of NVAX sold 16,749 shares for a total of $997,068.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
Read More on NVAX:
